Active, not recruitingPhase 2NCT04679870
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
Studying Primary myelofibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Galecto Biotech AB
- Principal Investigator
- Richard F Schlenk, MDUniversitätsklinikum Heidelberg, Germany
- Intervention
- GB2064(drug)
- Enrollment
- 21 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (11)
- MD Andersson Cancer Hospital, Houston, Texas, United States
- Woden Dermatology, Canberra, Australia
- Heinrich-Heine-University Dusseldorf, Düsseldorf, Germany
- Universitätsklinikum Heidelberg, Heidelberg, Germany
- Universität Leipzig, Leipzig, Germany
- Klinikum rechts der Isar der Technischen Universitaet Munchen, München, Germany
- University of Bologna Sant Orsola Malpighi, Bologna, Italy
- Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
- ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- Azienda Ospedaliero-Universitaria San Luigi Gonzaga di Orbassano, Orbassano, Italy
- Azienda Socio-Sanitaria Territoriale dei Sette Laghi, Varese, Italy
Collaborators
OPIS s.r.l
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04679870 on ClinicalTrials.govOther trials for Primary myelofibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07104799Momelotinib During and After HCT in MyelofibrosisMassachusetts General Hospital
- RECRUITINGPHASE3NCT07317700A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT07128381Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)M.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT06887803A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK InhibitorsiOnctura
- RECRUITINGPHASE1, PHASE2NCT07281781Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone MarrowUniversity of California, Irvine
- ACTIVE NOT RECRUITINGNCT07342712Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation LevelsFirst Affiliated Hospital of Zhejiang University
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06909136A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With MyelofibrosisSuzhou Junjing BioSciences Co., Ltd.
- RECRUITINGPHASE2NCT06770842Ropeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisThe University of Hong Kong